ADVFN - Advanced Financial Network.
HOME» NASDAQ » F » FACT Stock Price » FACT Stock News

Facet Biotech Share News

 Facet Biotech (mm) Stock Price
FACT Stock Price
 Facet Biotech (mm) Stock Chart
FACT Stock Chart
 Facet Biotech (mm) Stock News
FACT Stock News
 Facet Biotech (mm) Company Information
FACT Company Information
 Facet Biotech (mm) Stock Trades
FACT Stock Trades

Biogen Idec Reiterates Facet Bid Is 'Best And Final Offer'

DOW JONES NEWSWIRES A day after Facet Biotech Corp.'s (FACT) board rejected Biogen Idec Inc.'s (BIIB) raised $420 million acquisition offer, the biotechnology firm again said the bid represents its "best and final offer." Biogen's shares were recently up 29 cents to $48.55, while Facet's fell 2.8% to $17.46. Facet's stock has surged 85% so far this year. Last week, Biogen boosted its bid 21% to $17.50 a share after Facet had rebuffed its original offer at $14.50. On Thursday, Facet said the offer was "inadequate," although it opened the possibility of entering due-diligence talks. On Friday, Biogen encouraged Facet shareholders to tender their shares before the offer expires Dec. 16, saying it "fairly values Facet." Unless holders tender a majority of the outstanding shares by the expiration date, Biogen said it will walk away. For its part, Facet has argued that Biogen's offer doesn't put much value on its product pipeline and operations. The drug developer has stressed there's continued interest from other potential suitors. A combination of the two biotechnology firms, which already collaborate on multiple sclerosis and oncology drugs, would join companies with focuses on autoimmune disease and cancer. -By John Kell, Dow Jones Newswires; 212-416-2480;

Stock News for Facet Biotech (FACT)
No Recent News Available

Facet Biotech and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations